Intermolecularが2018年第2四半期決算を発表（後半）
Intermolecularが2018年第2四半期決算を発表（後半）
AsiaNet 74682 （1371）
Intermolecular, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts, Unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2018 2017 2018 2017
Revenue:
Program revenue $ 9,365 $ 6,480 $ 18,621 $ 13,291
Licensing and
royalty revenue 437 1,609 856 4,742
Total revenue 9,802 8,089 19,477 18,033
Cost of revenue:
Cost of program
revenue 2,856 2,545 6,231 5,242
Cost of licensing
and royalty revenue 3 2 4 292
Total cost of
revenue 2,859 2,547 6,235 5,534
Gross profit 6,943 5,542 13,242 12,499
Operating expenses:
Research and
development 4,056 5,385 8,087 12,494
Sales and marketing 858 931 1,654 2,412
General and
administrative 1,748 2,217 4,034 5,225
Restructuring
charges -- 3 -- 1,350
Total operating
expenses 6,662 8,536 13,775 21,481
Income (Loss) from
operations 281 (2,994) (533) (8,982)
Other income
(expense):
Interest income
(expense), net 140 58 245 113
Other income
(expense), net 75 82 162 179
Total other
income
(expense), net 215 140 407 292
Income (Loss) before
provision for
income taxes 496 (2,854) (126) (8,690)
Provision for income
taxes -- -- 1 1
Net income (loss) $ 496 $ (2,854) $ (127) $ (8,691)
Earnings (loss) per
share:
Basic $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Diluted $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Weighted-average
number of shares used
in computing earnings
(loss) per share
Basic 49,672,739 49,554,701 49,627,584 49,537,074
Diluted 50,059,639 49,554,701 49,627,584 49,537,074
Intermolecular, Inc.
Condensed Consolidated Balance Sheets
(In thousands, Unaudited)
As of June 30, 2018 As of December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents $ 4,347 $ 6,090
Short-term investments 25,662 18,060
Total cash, cash equivalents
and short-term investments 30,009 24,150
Accounts receivable 1,920 5,519
Prepaid expenses and other
current assets 725 1,069
Total current assets 32,654 30,738
Long-term investments 1,283 1,657
Materials inventory 2,836 2,781
Property and equipment, net 4,171 5,913
Intangible assets, net 2,382 2,620
Other assets 551 600
Total assets $ 43,877 $ 44,309
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 145 $ 928
Accrued liabilities 1,054 865
Accrued compensation and
employee benefits 2,494 2,535
Deferred revenue 309 941
Total current liabilities 4,002 5,269
Other long-term liabilities 2,808 2,967
Total liabilities 6,810 8,236
Stockholders' equity:
Common stock 50 50
Additional paid-in capital 215,449 214,796
Accumulated other
comprehensive loss (43) (35)
Accumulated deficit (178,389) (178,738)
Total stockholders' equity 37,067 36,073
Total liabilities and
stockholders' equity $ 43,877 $ 44,309
Intermolecular, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands, Unaudited)
Six Months Ended June 30,
2018 2017
Cash flows from operating activities:
Net loss $ (127) $ (8,691)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation, amortization and
accretion 2,693 3,597
Stock-based compensation 482 978
(Gain) loss on disposal of property
and equipment -- (7)
Changes in operating assets and
liabilities:
Accounts receivable 4,074 2,221
Prepaid expenses and other assets 393 515
Materials inventory (134) 373
Accounts payable (750) 743
Accrued and other liabilities (67) 4
Deferred revenue (633) 211
Net cash (used in) provided by
operating activities 5,931 (56)
Cash flows from investing activities:
Purchase of investments (19,367) (11,897)
Redemption of investments 12,010 13,215
Purchase of property and equipment (489) (521)
Proceeds from sale of equipment -- 10
Net cash (used in) provided by
investing activities (7,846) 807
Cash flows from financing activities:
Payment of capital leases -- (11)
Proceeds from exercise of common
stock options 172 --
Net cash (used in) provided by
financing activities 172 (11)
Net increase (decrease) in cash and
cash equivalents (1,743) 740
Cash and cash equivalents at beginning
of period 6,090 5,759
Cash and cash equivalents at end of period $ 4,347 $ 6,499
Intermolecular, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts and percentages, Unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2018 2017 2018 2017
GAAP cost of net
revenue $ 2,859 $ 2,547 $ 6,235 $ 5,534
Stock-based
compensation
expense (a) (39) (41) (92) (106)
Non-GAAP cost of net
revenue $ 2,820 $ 2,506 $ 6,143 $ 5,428
GAAP gross profit $ 6,943 $ 5,542 $ 13,242 $ 12,499
Stock-based
compensation
expense (a) 39 41 92 106
Non-GAAP gross profit $ 6,982 $ 5,583 $ 13,334 $ 12,605
As a percentage of
net revenue:
GAAP gross margin 70.8% 68.5% 68.0% 69.3%
Non-GAAP gross
margin 71.2% 69.0% 68.5% 69.9%
GAAP operating income
(loss) $ 281 $ (2,994) $ (533) $ (8,982)
Stock-based
compensation
expense (a):
- Cost of net
revenue 39 41 92 106
- Research and
development 59 63 114 245
- Sales and
marketing 21 10 51 69
- General and
administrative 93 208 225 558
Non-GAAP operating
income (loss) $ 493 $ (2,672) $ (51) $ (8,004)
GAAP net income
(loss) $ 496 $ (2,854) $ (127) $ (8,691)
Stock-based
compensation
expense (a) 212 322 482 978
Non-GAAP net income
(loss) $ 708 $ (2,532) $ 355 $ (7,713)
GAAP net income
(loss) $ 496 $ (2,854) $ (127) $ (8,691)
Interest (income)
expense, net (140) (58) (245) (113)
Provision for taxes -- -- 1 1
Depreciation,
amortization,
impairments and
accretion 1,270 1,619 2,693 3,597
Restructuring
charges (b) -- 3 -- 1,350
Stock-based
compensation
expense (a) 212 322 482 978
Adjusted EBITDA $ 1,838 $ (968) $ 2,804 $ 2.878
Shares used in
computing basic and
diluted earnings
per share:
Basic 49,672,739 49,554,701 49,627,584 49,537,074
Diluted 50,059,639 49,554,701 49,627,584 49,537,074
GAAP earnings (loss)
per share:
Basic $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Diluted $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Non-GAAP earnings
(loss) per share:
Basic $ 0.01 $ (0.05) $ 0.01 $ (0.16)
Diluted $ 0.01 $ (0.05) $ 0.01 $ (0.16)
(a) Stock-based compensation reflects expense recorded relating to stock-
based awards. The Company excludes this item when it evaluates the
continuing operational performance of the Company, as management
believes this provides it a meaningful understanding of its core
operating performance.
(b) Restructuring charges incurred in connection with a reduction in
headcount primarily comprised of employee severance and benefit costs.
Intermolecular, Inc.
Third Quarter 2018 Outlook
Reconciliation of GAAP Net Income/Loss to Non-GAAP Net Income
(In thousands, except per share amounts, Unaudited)
GAAP net loss range $(1,700) - $(2,800)
Stock-based compensation $300 - $300
Non-GAAP net income range $(1,400) - $(2,500)
GAAP and Non-GAAP diluted shares 49,700
GAAP net loss per share range $(0.04) - $(0.06)
Non-GAAP net income per share range $(0.03) - $(0.05)
▽企業問い合わせ先
Bill Roeschlein
Intermolecular, Inc.
Chief Financial Officer
bill.roeschlein@intermolecular.com
+1 (408) 582-5415
▽投資家問い合わせ先
Matt Glover or NajimMostamand, CFA
Liolios Group, Inc.
IMI@liolios.com
+1 (949) 574-3860
Logo - https://mma.prnewswire.com/media/327096/Intermolecular_Logo.jpg
ソース：Intermolecular, Inc.
Intermolecular Reports Second Quarter 2018 Financial Results（Part 2）
PR74682
Intermolecular, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share amounts, Unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2018 2017 2018 2017
Revenue:
Program revenue $ 9,365 $ 6,480 $ 18,621 $ 13,291
Licensing and
royalty revenue 437 1,609 856 4,742
Total revenue 9,802 8,089 19,477 18,033
Cost of revenue:
Cost of program
revenue 2,856 2,545 6,231 5,242
Cost of licensing
and royalty revenue 3 2 4 292
Total cost of
revenue 2,859 2,547 6,235 5,534
Gross profit 6,943 5,542 13,242 12,499
Operating expenses:
Research and
development 4,056 5,385 8,087 12,494
Sales and marketing 858 931 1,654 2,412
General and
administrative 1,748 2,217 4,034 5,225
Restructuring
charges -- 3 -- 1,350
Total operating
expenses 6,662 8,536 13,775 21,481
Income (Loss) from
operations 281 (2,994) (533) (8,982)
Other income
(expense):
Interest income
(expense), net 140 58 245 113
Other income
(expense), net 75 82 162 179
Total other
income
(expense), net 215 140 407 292
Income (Loss) before
provision for
income taxes 496 (2,854) (126) (8,690)
Provision for income
taxes -- -- 1 1
Net income (loss) $ 496 $ (2,854) $ (127) $ (8,691)
Earnings (loss) per
share:
Basic $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Diluted $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Weighted-average
number of shares used
in computing earnings
(loss) per share
Basic 49,672,739 49,554,701 49,627,584 49,537,074
Diluted 50,059,639 49,554,701 49,627,584 49,537,074
Intermolecular, Inc.
Condensed Consolidated Balance Sheets
(In thousands, Unaudited)
As of June 30, 2018 As of December 31, 2017
ASSETS
Current assets:
Cash and cash equivalents $ 4,347 $ 6,090
Short-term investments 25,662 18,060
Total cash, cash equivalents
and short-term investments 30,009 24,150
Accounts receivable 1,920 5,519
Prepaid expenses and other
current assets 725 1,069
Total current assets 32,654 30,738
Long-term investments 1,283 1,657
Materials inventory 2,836 2,781
Property and equipment, net 4,171 5,913
Intangible assets, net 2,382 2,620
Other assets 551 600
Total assets $ 43,877 $ 44,309
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 145 $ 928
Accrued liabilities 1,054 865
Accrued compensation and
employee benefits 2,494 2,535
Deferred revenue 309 941
Total current liabilities 4,002 5,269
Other long-term liabilities 2,808 2,967
Total liabilities 6,810 8,236
Stockholders' equity:
Common stock 50 50
Additional paid-in capital 215,449 214,796
Accumulated other
comprehensive loss (43) (35)
Accumulated deficit (178,389) (178,738)
Total stockholders' equity 37,067 36,073
Total liabilities and
stockholders' equity $ 43,877 $ 44,309
Intermolecular, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands, Unaudited)
Six Months Ended June 30,
2018 2017
Cash flows from operating activities:
Net loss $ (127) $ (8,691)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation, amortization and
accretion 2,693 3,597
Stock-based compensation 482 978
(Gain) loss on disposal of property
and equipment -- (7)
Changes in operating assets and
liabilities:
Accounts receivable 4,074 2,221
Prepaid expenses and other assets 393 515
Materials inventory (134) 373
Accounts payable (750) 743
Accrued and other liabilities (67) 4
Deferred revenue (633) 211
Net cash (used in) provided by
operating activities 5,931 (56)
Cash flows from investing activities:
Purchase of investments (19,367) (11,897)
Redemption of investments 12,010 13,215
Purchase of property and equipment (489) (521)
Proceeds from sale of equipment -- 10
Net cash (used in) provided by
investing activities (7,846) 807
Cash flows from financing activities:
Payment of capital leases -- (11)
Proceeds from exercise of common
stock options 172 --
Net cash (used in) provided by
financing activities 172 (11)
Net increase (decrease) in cash and
cash equivalents (1,743) 740
Cash and cash equivalents at beginning
of period 6,090 5,759
Cash and cash equivalents at end of period $ 4,347 $ 6,499
Intermolecular, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts and percentages, Unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2018 2017 2018 2017
GAAP cost of net
revenue $ 2,859 $ 2,547 $ 6,235 $ 5,534
Stock-based
compensation
expense (a) (39) (41) (92) (106)
Non-GAAP cost of net
revenue $ 2,820 $ 2,506 $ 6,143 $ 5,428
GAAP gross profit $ 6,943 $ 5,542 $ 13,242 $ 12,499
Stock-based
compensation
expense (a) 39 41 92 106
Non-GAAP gross profit $ 6,982 $ 5,583 $ 13,334 $ 12,605
As a percentage of
net revenue:
GAAP gross margin 70.8% 68.5% 68.0% 69.3%
Non-GAAP gross
margin 71.2% 69.0% 68.5% 69.9%
GAAP operating income
(loss) $ 281 $ (2,994) $ (533) $ (8,982)
Stock-based
compensation
expense (a):
- Cost of net
revenue 39 41 92 106
- Research and
development 59 63 114 245
- Sales and
marketing 21 10 51 69
- General and
administrative 93 208 225 558
Non-GAAP operating
income (loss) $ 493 $ (2,672) $ (51) $ (8,004)
GAAP net income
(loss) $ 496 $ (2,854) $ (127) $ (8,691)
Stock-based
compensation
expense (a) 212 322 482 978
Non-GAAP net income
(loss) $ 708 $ (2,532) $ 355 $ (7,713)
GAAP net income
(loss) $ 496 $ (2,854) $ (127) $ (8,691)
Interest (income)
expense, net (140) (58) (245) (113)
Provision for taxes -- -- 1 1
Depreciation,
amortization,
impairments and
accretion 1,270 1,619 2,693 3,597
Restructuring
charges (b) -- 3 -- 1,350
Stock-based
compensation
expense (a) 212 322 482 978
Adjusted EBITDA $ 1,838 $ (968) $ 2,804 $ 2.878
Shares used in
computing basic and
diluted earnings
per share:
Basic 49,672,739 49,554,701 49,627,584 49,537,074
Diluted 50,059,639 49,554,701 49,627,584 49,537,074
GAAP earnings (loss)
per share:
Basic $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Diluted $ 0.01 $ (0.06) $ (0.00) $ (0.18)
Non-GAAP earnings
(loss) per share:
Basic $ 0.01 $ (0.05) $ 0.01 $ (0.16)
Diluted $ 0.01 $ (0.05) $ 0.01 $ (0.16)
(a) Stock-based compensation reflects expense recorded relating to stock-
based awards. The Company excludes this item when it evaluates the
continuing operational performance of the Company, as management
believes this provides it a meaningful understanding of its core
operating performance.
(b) Restructuring charges incurred in connection with a reduction in
headcount primarily comprised of employee severance and benefit costs.
Intermolecular, Inc.
Third Quarter 2018 Outlook
Reconciliation of GAAP Net Income/Loss to Non-GAAP Net Income
(In thousands, except per share amounts, Unaudited)
GAAP net loss range $(1,700) - $(2,800)
Stock-based compensation $300 - $300
Non-GAAP net income range $(1,400) - $(2,500)
GAAP and Non-GAAP diluted shares 49,700
GAAP net loss per share range $(0.04) - $(0.06)
Non-GAAP net income per share range $(0.03) - $(0.05)
Corporate Contact:
Bill Roeschlein
Intermolecular, Inc.
Chief Financial Officer
bill.roeschlein@intermolecular.com
+1 (408) 582-5415
Investor Contact:
Matt Glover or Najim Mostamand, CFA
Liolios Group, Inc.
IMI@liolios.com
+1 (949) 574-3860
Logo - https://mma.prnewswire.com/media/327096/Intermolecular_Logo.jpg
SOURCE: Intermolecular, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
